125 related articles for article (PubMed ID: 38513258)
1. Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.
Liu Y; Hu K; Jian L; Duan Y; Zhang M; Kuang Y
J Dermatolog Treat; 2024 Dec; 35(1):2331782. PubMed ID: 38513258
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
4. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
6. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Strober B; Armstrong A; Rubant S; Patel M; Wu T; Photowala H; Crowley J
J Dermatolog Treat; 2022 Nov; 33(7):2991-2996. PubMed ID: 35839335
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
Fonseca E; Iglesias R; Paradela S; Fernández-Torres RM; Elberdín L
J Dermatolog Treat; 2015 Jun; 26(3):217-22. PubMed ID: 24920071
[TBL] [Abstract][Full Text] [Related]
9. HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.
Talamonti M; Galluzzo M; Zangrilli A; Papoutsaki M; Egan CG; Bavetta M; Tambone S; Fargnoli MC; Bianchi L
Mol Diagn Ther; 2017 Jun; 21(3):295-301. PubMed ID: 28130758
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics.
Kim TR; Won Y; Kim Y; Won SH; Bae KN; Lee J; Shin K; Kim H; Ko H; Kim MB; Kim B
Eur J Dermatol; 2023 Oct; 33(5):518-523. PubMed ID: 38297928
[TBL] [Abstract][Full Text] [Related]
14. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
15. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
Di Lernia V; Bianchi L; Guerriero C; Stingeni L; Gisondi P; Filoni A; Guarneri C; Belloni Fortina A; Lasagni C; Simonetti O; Neri I; Zangrilli A; Moretta G; Hansel K; Casanova DM; Girolomoni G; Cannavò SP; Bonamonte D
Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
[TBL] [Abstract][Full Text] [Related]
17. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena GA; Galluccio A; De Simone C; Mastrandrea V; Buquicchio R; La Greca S; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pità O; Pezza M; D Agostino M; Vernaci R; Miracapillo A; Valenti G; Cassano N
Int J Immunopathol Pharmacol; 2009; 22(1):227-33. PubMed ID: 19309570
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.
Piaserico S; Cazzaniga S; Chimenti S; Giannetti A; Maccarone M; Picardo M; Peserico A; Naldi L;
J Am Acad Dermatol; 2014 Feb; 70(2):257-62.e3. PubMed ID: 24355410
[TBL] [Abstract][Full Text] [Related]
20. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
